David D. Dore, PharmD, PhD; Kate L. Lapane, PhD; Amal N. Trivedi, MD, MPH; Vincent Mor, PhD; Martin A. Weinstock, MD, PhD
Acknowledgment: The authors thank Kimberly Marcolivio, MEd; Robert Dyer, MD, MPH; and Margaret M. Boyle for their thoughtful assistance. They also acknowledge members of the VATTC trial group: study chairman Martin A. Weinstock, MD, PhD; Executive Committee members Martin A. Weinstock, MD, PhD, Russell P. Hall, MD, Mark F. Naylor, MD, Julia E. Vertrees, PharmD, John J. DiGiovanna, MD, and Stephen F. Bingham, PhD; study dermatopathologists Clifford R. White, Jr., MD, and Michael Piepkorn, MD; site investigators Russell P. Hall, MD, Mark F. Naylor, MD, David Eilers, MD, Jonette E. Keri, MD, James Kalivas, MD, Gary W. Cole, MD, Catherine Yanna, PA-C, and Robert S. Kirsner, MD; and study coordinator Kimberly Marcolivio, MEd.
Grant Support: Dr. Weinstock was supported by the Department of Veterans Affairs Office of Research and Development (CSP 402), and Dr. Dore was supported by the Agency for Healthcare Research and Quality (grant 5T32HS000011-21). Additional support was received from the American Cancer Society. Dr. Weinstock also received support from the National Institutes of Health (grants R01CA106592, R01CA106807, R25CA087972, and R01AR49342).
Potential Financial Conflicts of Interest:Consultancies: D.D. Dore (Pfizer). Grants received: K.L. Lapane (Pfizer).
Reproducible Research Statement:Study protocol and statistical code: Available from Dr. Dore (e-mail, email@example.com). Data set: Not available.
Requests for Single Reprints: David D. Dore, PharmD, PhD, i3 Drug Safety, 950 Winter Street, Suite 3800, Waltham, MA 02451; e-mail, firstname.lastname@example.org.
Current Author Addresses: Dr. Dore: i3 Drug Safety, 950 Winter Street, Suite 3800, Waltham, MA 02451.
Drs. Lapane, Trivedi, and Mor: Brown University, Box G-ST, 121 South Main Street, Providence, RI 02903.
Dr. Weinstock: Dermatoepidemiology Unit, Veterans Affairs Medical Center, 111D, 830 Chalkstone Avenue, Providence, RI 02908.
Author Contributions: Conception and design: D.D. Dore, K.L. Lapane, V. Mor, M.A. Weinstock.
Analysis and interpretation of the data: D.D. Dore, K.L. Lapane, A.N. Trivedi, M.A. Weinstock.
Drafting of the article: D.D. Dore.
Critical revision of the article for important intellectual content: D.D. Dore, K.L. Lapane, A.N. Trivedi, V. Mor, M.A. Weinstock.
Final approval of the article: D.D. Dore, K.L. Lapane, A.N. Trivedi, V. Mor, M.A. Weinstock.
Provision of study materials or patients: M.A. Weinstock.
Statistical expertise: D.D. Dore, K.L. Lapane.
Obtaining of funding: M.A. Weinstock.
Administrative, technical, or logistic support: D.D. Dore, K.L. Lapane, V. Mor, M.A. Weinstock.
ClinicalTrials.gov registration number: NCT00007631.
Dore D., Lapane K., Trivedi A., Mor V., Weinstock M.; Association Between Statin Use and Risk for Keratinocyte Carcinoma in the Veterans Affairs Topical Tretinoin Chemoprevention Trial. Ann Intern Med. 2009;150:9-18. doi: 10.7326/0003-4819-150-1-200901060-00004
Download citation file:
Published: Ann Intern Med. 2009;150(1):9-18.
Recent evidence suggests that statins may prevent cancer.
To quantify the association between statin use and the occurrence of keratinocyte carcinoma in high-risk veterans.
6 Veterans Affairs medical centers.
1037 participants of the Veterans Affairs Topical Tretinoin Chemoprevention Trial, a randomized, multicenter, double-blind, vehicle-controlled trial of topical tretinoin, 0.1%, for prevention of keratinocyte carcinoma conducted from November 1998 to November 2004.
Time to first occurrence of keratinocyte carcinoma on the face or ears. Participants using a statin at randomization, according to the Veterans Affairs Pharmacy Benefits Management database, were considered exposed. Study dermatologists conducted physical examinations at baseline and every 6 months during follow-up. The association between statin use at randomization and the outcome was evaluated by using propensity score matching (nÂ = 608) and Cox proportional hazards regression (nÂ = 1037).
Among the 1037 participants, 37% used a statin at randomization (nÂ = 397) for a median duration of at least 900 days over a median follow-up of 3.5 years. In the propensity scoreâ€“matched analysis, statin use at randomization was not associated with keratinocyte carcinoma (rate ratio, 0.92 [95% CI, 0.73 to 1.16]), a finding that was consistent with the estimates derived from the Cox proportional hazards regression (rate ratio, 0.84 [CI, 0.70 to 1.02]).
The extent of residual confounding is unknown, and the confidence bounds around the measures of association were wide. These data may not be generalizable to lower-risk populations.
These data show no conclusive or consistent relationship between long-term statin use and risk for keratinocyte carcinoma.
Department of Veterans Affairs, Agency for Healthcare Research and Quality, American Cancer Society, and National Institutes of Health.
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Cardiology, Hematology/Oncology, Dyslipidemia, Coronary Risk Factors.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only